Any idea about “Tiny Start-Up Wins Epic Verdict… Poised for a 28,700% Sales Surge”

By Brian, February 23, 2018

Tiny Start-Up Wins Epic Verdict…
Poised for a 28,700% Sales Surge
Secure an early stake now and you could be $2.8 million richer within 18 months.
Hi, Michael Robinson here. Thank you for viewing my presentation.
I’ve never been as excited about an opportunity as I am about this one today.
The magnitude of what is about to take place is nearly beyond comprehension.
I’m talking about a microscopic gene-editing device that can actually reverse genetic mutations at the cellular level…
And virtually ERASE deadly scourges – like cancer, blindness, Alzheimer’s, heart disease, diabetes, and more – WITHOUT dangerous drugs, risky surgery, or devastating chemotherapy.
Bloomberg hit the nail on the head when it said, “This is the discovery of the century that will change the world.”
And at the center of this frenzy sits one tiny $6 million company that’s about to go absolutely vertical.
These guys just won in a landmark patent case for control of this device.
Now they’re positioned to haul in a potential $97 billion in royalties and licensing fees.
In fact, with 34 registered patents – and another 500 patents pending – this tiny company could DOMINATE the U.S. medical markets for decades to come.
And today you have a chance to pocket huge windfalls as a ground floor investor in this trans formative company.
Make no mistake…
Over the next 18 months, this tiny company’s revenues could skyrocket by 28,700%.
That means, by getting in now before this company becomes a household name, you’ll have the opportunity to turn:

Every $1,000 into $287,000…

https://purchases.moneymappress.com/TIMCNR2/ETIMU234/index.htm?pageNumber=2&email=briandmoon%40gmail.com&a=8&o=70080&s=103363&u=10855585&l=2354196&r=MC2&vid=rVX6VX&g=0&h=true&link_source=button&vidTime=0

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

2
Share your thoughts...

avatar
2 Comment threads
0 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
2 Comment authors
schultzdcsbriandmoon Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

schultzdcs
Member
👍1

Yes, its Editas (EDIT). But the patent dispute was resolved a year ago. Not new news. They do have a good proprietary portfolio though. So not a bad stock in the CRISPR technology field.

Add a Topic
5211
Add a Topic
5971
Add a Topic
5254